News|Articles|May 13, 2026

End of FDA Commissioner Makary’s Tumultuous Tenure Leaves Agency in Transition

FDA Commissioner Marty Makary’s departure caps a turbulent tenure marked by leadership instability, industry pushback, and a series of regulatory controversies that complicated drug development for sponsors and CROs.

FDA Commissioner Marty Makary, MD, MPH, resigned Tuesday, according to The Associated Press, just 13 months after being confirmed to lead the agency, following months of mounting pressure from pharmaceutical executives, anti-abortion activists, vaping industry lobbyists, and other political allies of President Trump.1

Related to this article

The Next Evolution of Patient-Centered Trials Starts with Design
Decentralized trial success depends less on how far activities move away from sites than on matching each activity’s delivery model to participant burden, site readiness, and data integrity, using patient intelligence to decide where flexibility helps and where site-based care remains essential.
© putilov_denis - © putilov_denis - stock.adobe.com
Sponsors rigorously vet CROs for oncology expertise but rarely apply the same scrutiny to the IRB reviewing their trials, even though increasingly complex protocols require reviewers with substantive therapeutic knowledge, not just a rostered oncologist.